Wegovy (semaglutide) is licensed in the UK with a specific titration schedule that builds up to a full maintenance dose over several months. But not every patient ends up on that full dose — and not every patient needs to. Some stay long-term at a lower dose because it works for them, because the higher doses caused side effects they couldn't live with, or because they've already reached their weight goal and the maintenance question changes. This article walks through what "low dose" means clinically, when it makes sense, and how to have that conversation with your clinician.
Wegovy's standard titration vs maintenance
The standard UK Wegovy schedule starts at 0.25 mg once weekly for four weeks, then steps up to 0.5 mg, 1.0 mg, 1.7 mg, and eventually 2.4 mg — the licensed maintenance dose. The four-week interval at each step exists for two reasons: semaglutide reaches steady-state plasma levels at around four to five weeks, and gastrointestinal side effects are most pronounced in the first one to two weeks after a dose change.
The 2.4 mg maintenance dose is what the STEP clinical-trial programme tested most rigorously and is the dose that produced the well-known average weight loss figures. It is, however, not the only dose a clinician will ever leave a patient on. UK prescribers regularly maintain patients at 1.0 mg or 1.7 mg long-term when that fits the patient better.
When clinicians consider lower-dose maintenance
There is no single rule, but a few patterns come up repeatedly in consultations:
- Side-effect tolerability. If 1.7 mg or 2.4 mg caused persistent nausea, constipation, fatigue, or reflux that didn't settle, a lower maintenance dose may give most of the benefit with significantly less burden.
- Steady response at a lower dose. Some patients lose weight steadily on 1.0 mg or 1.7 mg. Pushing higher just because the licence allows it isn't always the right call.
- Goal achieved. When a patient has reached their agreed weight goal, the conversation moves from titration to maintenance. Some clinicians step the dose back down rather than holding the full dose indefinitely.
- Coexisting conditions or medications. Some clinical situations make higher doses less appropriate, and the lower dose is a reasonable long-term plan.
- Patient preference, with clinician agreement. Some patients value the milder side-effect profile of a lower dose enough that they accept slightly slower weight loss.
How efficacy compares between lower and full dose
Trial data show a dose-response relationship for semaglutide in weight management — on average, the higher the dose, the greater the weight loss across a population. But that is a population-level statement, not a personal one. Individual response varies widely. Some patients lose nearly as much at 1.7 mg as others lose at 2.4 mg. The right way to read the trial data is as a probability distribution, not a target.
The other thing worth saying: the STEP-4 trial showed that continuing semaglutide is more important for weight maintenance than the specific dose. Stopping treatment is associated with weight regain regardless of which dose the patient was on. For many patients, the practical question is "stay on something" versus "stop", not "high dose" versus "low dose".
Side-effect trade-offs of staying low
Lower Wegovy doses are usually better tolerated. Common side effects — nausea, constipation, reflux, fatigue — tend to be milder at 1.0 mg and 1.7 mg than at 2.4 mg, particularly for patients who struggled with the higher dose during titration.
That said, a few caveats:
- "Lower" doesn't mean "no side effects". Some people still get GI symptoms at 0.5 mg or 1.0 mg.
- If symptoms are severe, the answer isn't always to drop a dose — sometimes it's to look at hydration, eating pattern, or anti-emetic options first.
- Serious adverse events (pancreatitis, gallbladder events, severe dehydration) can occur at any dose and warrant urgent clinical review. They aren't restricted to high-dose patients.
When to ask a clinician to step you down
If you're considering asking your clinician about a lower maintenance dose, useful prompts at a review include:
- "Side effects at the current dose are still significant after several weeks. Could we trial a lower dose?"
- "I've reached my target weight. What would maintenance look like for me?"
- "My weight loss has been steady at this dose. Do I need to keep stepping up?"
- "I'd like to understand the trade-off between weight loss and side effects at a lower dose."
These are conversation starters, not requests. Your clinician will weigh the evidence and your individual picture before recommending a plan.
What stopping vs maintaining looks like
One thing the trial evidence is clear about: stopping semaglutide is generally associated with weight regain. STEP-4 showed that patients who stopped after the initial weight-loss phase tended to regain a significant proportion of their loss; patients who continued maintained their loss far more reliably.
For patients weighing up "stop completely" versus "stay at a lower dose", the data tend to favour continuing at some dose. The conversation about which dose is then a separate one. A clinician will help you read both — short-term comfort, long-term outcomes, and what fits your life.
Working with your Farmeci clinician
Decisions about staying low, stepping up, stepping down, or stopping are joint ones, made at a regular review. Bring honest information about how you're feeling on the current dose: side effects you're noticing, weight trajectory, mood, sleep, anything that's changed in your life. Your clinician will translate that into a sensible next step. There's no fixed "right" answer about which Wegovy dose anyone "should" be on — there's the dose that fits you, your tolerability, and your goals at this point in your journey.